Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction

Wan,Qiang; Liu,Zhongyong; Yang,Yuping; Cui,Xiaobing

doi:10.3892/ijmm.2018.3440

Suppressive effects of berberine on atherosclerosis via downregulating visfatin expression and attenuating visfatin-induced endothelial dysfunction

Authors:
- Qiang Wan
- Zhongyong Liu
- Yuping Yang
- Xiaobing Cui
View Affiliations

Affiliations: Department of Medical Cardiology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi 330006, P.R. China, School of Traditional Chinese Medicine, Southern Medical University, Guangzhou, Guangdong 510515, P.R. China
Published online on: January 30, 2018 https://doi.org/10.3892/ijmm.2018.3440
Pages: 1939-1948
Copyright: © Wan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Berberine (BBR) possesses significant anti-atherosclerosis properties. Visfatin is one of the most promising biomarkers of incoming atherosclerosis. However, research on the effect of BBR on regulating visfatin expression in atherogenesis remains largely unknown. In this study, we investigated the effects of BBR on visfatin expression and atherogenesis in apolipoprotein E knockout (ApoE-/-) mice. The effect of BBR on attenuating visfatin-induced endothelial dysfunction was also evaluated in cultured human umbilical vein endothelial cells (HUVECs). In vivo experiments showed that BBR treatment (5 mg/kg/day) significantly reduced the serum levels of visfatin, lipid, interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α), the protein expression of visfatin, p-p38 MAPK and p-c-Jun N-terminal kinase (JNK) in mice aorta and the distribution of visfatin in the atherosclerotic lesions in ApoE-/- mice fed with a Western diet. In addition, in vitro experiments indicated that visfatin (100 µg/l) significantly increased apoptosis, the contents of IL-6 and TNF-α, the protein levels of p-p38 MAPK, p-JNK and Bax in HUVECs, which were reversed by BBR administration (50 µmol/l). Our findings suggest that BBR significantly ameliorates Western diet-induced atherosclerosis in ApoE-/- mice via downregulating visfatin expression, which is related to the inhibition of p38 MAPK and JNK signaling pathways and subsequent suppression of visfatin-induced endothelial dysfunction.

View Figures

View References

1	Ross R: Atherosclerosis - an inflammatory disease. N Engl J Med. 340:115–126. 1999. View Article : Google Scholar : PubMed/NCBI
2	Lee GY, Kim JH, Oh GT, Lee BH, Kwon IC and Kim IS: Molecular targeting of atherosclerotic plaques by a stabilin-2-specific peptide ligand. J Control Release. 155:211–217. 2011. View Article : Google Scholar : PubMed/NCBI
3	Lu H and Daugherty A: Atherosclerosis. Arterioscler Thromb Vasc Biol. 35:485–491. 2015. View Article : Google Scholar : PubMed/NCBI
4	Vanhoutte PM: Endothelial dysfunction: The first step toward coronary arteriosclerosis. Circ J. 73:595–601. 2009. View Article : Google Scholar : PubMed/NCBI
5	Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, et al: Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 307:426–430. 2005. View Article : Google Scholar
6	Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y and Inukai T: Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metabolism. 56:451–458. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dahl TB, Yndestad A, Skjelland M, Øie E, Dahl A, Michelsen A, Damås JK, Tunheim SH, Ueland T, Smith C, et al: Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation. 115:972–980. 2007. View Article : Google Scholar : PubMed/NCBI
8	Auguet T, Aragonès G, Guiu-Jurado E, Berlanga A, Curriu M, Martinez S, Alibalic A, Aguilar C, Camara ML, Hernández E, et al: Adipo/cytokines in atherosclerotic secretomes: Increased visfatin levels in unstable carotid plaque. BMC Cardiovasc Disord. 16:1492016. View Article : Google Scholar : PubMed/NCBI
9	Moschen AR, Kaser A, Enrich B, Mosheimer B, Theurl M, Niederegger H and Tilg H: Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol. 178:1748–1758. 2007. View Article : Google Scholar : PubMed/NCBI
10	Wan Q, Cui X, Shao J, Zhou F, Jia Y, Sun X, Zhao X, Chen Y, Diao J and Zhang L: Beijing ambient particle exposure accelerates atherosclerosis in ApoE knockout mice by upregulating visfatin expression. Cell Stress Chaperones. 19:715–724. 2014. View Article : Google Scholar : PubMed/NCBI
11	Zhou F, Pan Y, Huang Z, Jia Y, Zhao X, Chen Y, Diao J, Wan Q and Cui X: Visfatin induces cholesterol accumulation in macrophages through up-regulation of scavenger receptor-A and CD36. Cell Stress Chaperones. 18:643–652. 2013. View Article : Google Scholar : PubMed/NCBI
12	Lin CF, Chang YH, Liu JC, Chuang MT and Chien LN: Statin use associated with a reduced risk of pneumonia requiring hospitalization in patients with myocardial infarction: A nested case-control study. BMC Cardiovasc Disord. 16:242016. View Article : Google Scholar : PubMed/NCBI
13	Li H, He C, Wang J, Li X, Yang Z, Sun X, Fang L and Liu N: Berberine activates peroxisome proliferator-activated receptor gamma to increase atherosclerotic plaque stability in Apoe(−/−) mice with hyperhomocysteinemia. J Diabetes Investig. 7:824–832. 2016. View Article : Google Scholar : PubMed/NCBI
14	Chen FL, Yang ZH, Liu Y, Li LX, Liang WC, Wang XC, Zhou WB, Yang YH and Hu RM: Berberine inhibits the expression of TNFalpha, MCP-1, and IL-6 in AcLDL-stimulated macrophages through PPARgamma pathway. Endocrine. 33:331–337. 2008. View Article : Google Scholar : PubMed/NCBI
15	Fan X, Wang J, Hou J, Lin C, Bensoussan A, Chang D, Liu J and Wang B: Berberine alleviates ox-LDL induced inflammatory factors by up-regulation of autophagy via AMPK/mTOR signaling pathway. J Transl Med. 13:922015. View Article : Google Scholar : PubMed/NCBI
16	Huang Z, Wang L, Meng S, Wang Y, Chen T and Wang C: Berberine reduces both MMP-9 and EMMPRIN expression through prevention of p38 pathway activation in PMA-induced macrophages. Int J Cardiol. 146:153–158. 2011. View Article : Google Scholar
17	Zimetti F, Adorni MP, Ronda N, Gatti R, Bernini F and Favari E: The natural compound berberine positively affects macrophage functions involved in atherogenesis. Nutr Metab Cardiovasc Dis. 25:195–201. 2015. View Article : Google Scholar
18	Zhang SH, Reddick RL, Piedrahita JA and Maeda N: Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468–471. 1992. View Article : Google Scholar : PubMed/NCBI
19	Goon PK, Watson T, Shantsila E, Boos CJ and Lip GY: Standardization of circulating endothelial cell enumeration by the use of human umbilical vein endothelial cells. J Thromb Haemost. 5:870–872. 2007. View Article : Google Scholar : PubMed/NCBI
20	Whitman SC: A practical approach to using mice in atherosclerosis research. Clin Biochem Rev. 25:81–93. 2004.
21	Varma V, Yao-Borengasser A, Rasouli N, Bodles AM, Phanavanh B, Lee MJ, Starks T, Kern LM, Spencer HJ III, McGehee RE Jr, et al: Human visfatin expression: Relationship to insulin sensitivity, intramyocellular lipids, and inflammation. J Clin Endocrinol Metab. 92:666–672. 2007. View Article : Google Scholar
22	Zhong M, Tan HW, Gong HP, Wang SF, Zhang Y and Zhang W: Increased serum visfatin in patients with metabolic syndrome and carotid atherosclerosis. Clin Endocrinol (Oxf). 69:878–884. 2008. View Article : Google Scholar
23	El-Shishtawy SH, Mosbah O, Sherif N, Metwaly A, Hanafy A and Kamel L: Association between serum visfatin and carotid atherosclerosis in diabetic and non-diabetic patients on maintenance hemodialysis. Electron Physician. 8:1966–1972. 2016. View Article : Google Scholar : PubMed/NCBI
24	Shi KL, Qian JY, Qi L, Mao DB, Chen Y, Zhu Y and Guo XG: Atorvastatin antagonizes the visfatin-induced expression of inflammatory mediators via the upregulation of NF-κB activation in HCAECs. Oncol Lett. 12:1438–1444. 2016. View Article : Google Scholar : PubMed/NCBI
25	Zhao Li B, Liu Y, Meng H, Wang B, Qi J, Zhang T, Li H, Zhao T, Sun PH, et al: Visfatin destabilizes atherosclerotic plaques in apolipoprotein E-deficient mice. PLoS One. 11:e01482732016. View Article : Google Scholar : PubMed/NCBI
26	Zhao XN, Li YN and Wang YT: Interleukin-4 regulates macrophage polarization via the MAPK signaling pathway to protect against atherosclerosis. Genet Mol Res. 15:2016.
27	Zhang Y, Mu Q, Zhou Z, Song H, Zhang Y, Wu F, Jiang M, Wang F, Zhang W, Li L, et al: Protective effect of irisin on atherosclerosis via suppressing oxidized low density lipoprotein induced vascular inflammation and endothelial dysfunction. PLoS One. 11:e01580382016. View Article : Google Scholar : PubMed/NCBI
28	Yin X, Zhou L, Han F, Han J, Zhang Y, Sun Z, Zhao W, Wang Z and Zheng L: Beta-adrenoceptor activation by norepinephrine enhances lipopolysaccharide-induced matrix metallopro-teinase-9 expression through the ERK/JNK-c-Fos pathway in human THP-1 cells. J Atheroscler Thromb. 24:55–67. 2016. View Article : Google Scholar
29	Guo J, Wang L, Wang L, Qian S, Zhang D, Fang J and Pan J: Berberine protects human umbilical vein endothelial cells against LPS-induced apoptosis by blocking JNK-mediated signaling. Evid Based Complement Alternat Med. 2016:69839562016. View Article : Google Scholar : PubMed/NCBI
30	Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Böhm M and Nickenig G: Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. 94:534–541. 2004. View Article : Google Scholar
31	Ohta H, Wada H, Niwa T, Kirii H, Iwamoto N, Fujii H, Saito K, Sekikawa K and Seishima M: Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis. 180:11–17. 2005. View Article : Google Scholar : PubMed/NCBI
32	Kumar S, Kim CW, Simmons RD and Jo H: Role of flow-sensitive microRNAs in endothelial dysfunction and atherosclerosis: Mechanosensitive athero-miRs. Arterioscler Thromb Vasc Biol. 34:2206–2216. 2014. View Article : Google Scholar : PubMed/NCBI
33	Wang X, Guo Y, Wang C and Yu H, Yu X and Yu H: MicroRNA-142 3p Inhibits chondrocyte apoptosis and inflammation in osteoarthritis by targeting HMGB1. Inflammation. 39:1718–1728. 2016. View Article : Google Scholar : PubMed/NCBI
34	Choy JC, Granville DJ, Hunt DW and McManus BM: Endothelial cell apoptosis: Biochemical characteristics and potential implications for atherosclerosis. J Mol Cell Cardiol. 33:1673–1690. 2001. View Article : Google Scholar : PubMed/NCBI
35	Adams JM and Cory S: The Bcl-2 protein family: Arbiters of cell survival. Science. 281:1322–1326. 1998. View Article : Google Scholar : PubMed/NCBI
36	Furnkranz A, Schober A, Bochkov VN, Bashtrykov P, Kronke G, Kadl A, Binder BR, Weber C and Leitinger N: Oxidized phospholipids trigger atherogenic inflammation in murine arteries. Arterioscler Thromb Vasc Biol. 25:633–638. 2005. View Article : Google Scholar
37	Stein O and Stein Y: Atheroprotective mechanisms of HDL. Atherosclerosis. 144:285–301. 1999. View Article : Google Scholar : PubMed/NCBI